ClinicalTrials.gg
CompletedNCT07335198Updated Sep 21, 2026

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry

A Phase 1 interventional study of Efimosfermin alfa and Placebo in Non-alcoholic Fatty Liver Disease, sponsored by GlaxoSmithKline. Completed at 1 site in New Zealand. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Non-alcoholic Fatty Liver Disease with a site in New Zealand — 3 open to participants now, 3 under way, 3 of them phase 3. Non-alcoholic Fatty Liver Disease · New Zealand.

Enrollment
20th of 20
30 · median 258
Started
2026
the only one that year
Phase 1
2 of 20
none open now
Registered
20th of 20
by date
Lead sponsor
3 of 20
GlaxoSmithKline

Among the 20 studies in Non-alcoholic Fatty Liver Disease with a site in New Zealand, this one is the 20th largest by enrollment, is the only one that started in 2026, is one of 2 in phase 1, and was the 20th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

3 of the 20 studies in Non-alcoholic Fatty Liver Disease with a site in New Zealand are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in New Zealand have not opened yet or have stopped. Only those recruiting at a site in New Zealand →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Non-alcoholic Fatty Liver Disease with a site in New Zealand, or all of them as a file.
02

Study summary

This is a first time in Asia (FTIA) study designed to evaluate the safety, tolerability, pharmacokinetic (PK) and immunogenicity of efimosfermin alfa to healthy participants of Chinese, Japanese, and White/European ancestry.

03

Conditions studied

  • Non-alcoholic Fatty Liver Disease

Keywords

  • Efimosfermin alfa
  • Placebo
  • First time in Asia
  • Chinese
  • Japanese
  • White/Europeans
  • Pharmacokinetics
  • Safety
  • Immunogenicity
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants who are generally healthy as determined by medical evaluation

  • Body weight at least 50.0 kilograms (kg) for male participants or at least 45.0 kg for female participants
  • (BMI) within the range of 18.0 to 28.0 kilograms per square meter (kg/m\^2) (inclusive)
  • Male and female participants
  • Participants of Chinese ancestry are eligible if born in mainland China, Hong Kong, or Taiwan, and descendant of 2 ethnic Chinese parents and 4 ethnic Chinese grandparents; and have lived outside China, Hong Kong, or Taiwan for less than 10 years at the time of screening.
  • Participants of Japanese ancestry are eligible if born in Japan and descendant of 2 ethnic Japanese parents and 4 ethnic Japanese grandparents; and have lived outside Japan for less than 10 years at the time of screening.
  • Participants of White/European ancestry are eligible if self-identified as being of White/European ancestry, (that is [i.e.], from the original peoples of Europe) irrespective of current place of residence; and descendant of 2 parents and 4 grandparents of White/European ancestry (i.e., from the original peoples of Europe) irrespective of place of birth or current place of residence.

Exclusion criteria

Exclusion Criteria:

  • History or presence of disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
  • Current or chronic history of liver or biliary disease with the exception of Gilbert's syndrome or asymptomatic gallstones.
  • History of pancreatic injury, pancreatitis or other pancreatic disease; history of Type one Diabetes Mellitus (T1DM) or positive glutamic acid decarboxylase auto-antibodies, or major Type two Diabetes Mellitus (T2DM) complications including severe gastroparesis and autonomic neuropathy.
  • Abnormal blood pressure (defined as systolic Blood Pressure [BP] more than equal [>=]140 millimeters of mercury [mmHg] or diastolic BP >=90 mmHg measured based on the average of triplicate BP readings).
  • History of metabolic bone disorders including osteoporosis, osteopenia, or osteomalacia.
  • History of of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years.
  • (ALT) more than (>)1.5 * (ULN).
  • Total >1.5 * ULN
  • Known bleeding disorder.
  • History of immunodeficiency diseases, including a positive test result for (HIV).
  • Interval using Fridericia's Formula (QTcF) >=450 millisecond (msec)(male) or >=470 msec (female) at Screening Visit based on the average of triplicate ECGs.
  • Use of statins, other lipid lowering medications or hypertension medications unless on a stable dose for at least 3 months.
  • Use of other drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever was longer; or longer if required by local regulations.
  • Participants who have received native FGF21 or a FGF21 analog at any time in the past.
  • Intended use of over the counter (OTC) or prescription medication (including herbal medications) within 7 days prior to dosing and for the duration of study participation.
  • within 14 days prior to dosing and non-live vaccines for 7 days prior study dosing.
  • Current enrolment or participation in another clinical trial within the last 30 days before signing consent of current study.
  • Presence of surface antigen (HBsAg) or antibody at screening or within 3 months prior to the first dose of study intervention
  • A positive pre-study drug/alcohol screen
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Efimosfermin alfa in participants of Chinese Ancestry

    Healthy participants of Chinese ancestry will be randomized to receive efimosfermin alfa.

    Drug: Efimosfermin alfa

  • Experimental
    Efimosfermin alfa in participants of Japanese Ancestry

    Healthy participants of Japanese ancestry will be randomized to receive efimosfermin alfa.

    Drug: Efimosfermin alfa

  • Experimental
    Efimosfermin alfa in participants of White/European Ancestry

    Healthy participants of White/European ancestry will be randomized to receive efimosfermin alfa.

    Drug: Efimosfermin alfa

  • Placebo comparator
    Placebo in participants of Chinese Ancestry

    Healthy participants of Chinese ancestry will be randomized to receive Placebo.

    Drug: Placebo

  • Placebo comparator
    Placebo in participants of Japanese Ancestry

    Healthy participants of Japanese ancestry will be randomized to receive Placebo.

    Drug: Placebo

  • Placebo comparator
    Placebo in participants of White/European Ancestry

    Healthy participants of White/European ancestry will be randomized to receive Placebo.

    Drug: Placebo

Interventions

  • Efimosfermin alfa to be administered

  • DrugPlacebo

    Placebo to be administered

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events (AEs), treatment related AEs and serious adverse events (SAEs)

    Time frame: Up to 90 days

  2. Number of participants with clinically significant changes in hematology, chemistry and urinalysis parameters

    Time frame: Up to 90 days

  3. Number of participants with clinically significant changes in 12 Lead electrocardiogram (ECG)

    Time frame: Up to 90 days

  4. Number of participants with clinically significant changes in vital signs

    Time frame: Up to 90 days

  5. Area under the serum drug concentration versus time curve from time zero to the time of the last quantifiable concentration (AUC[0-t]) of efimosfermin alfa

    Time frame: Up to 90 days

  6. Area under the serum drug concentration versus time curve from time zero extrapolated to infinity (AUC[0-inf]) of efimosfermin alfa

    Time frame: Up to 90 days

  7. Maximum observed serum drug concentration, determined directly from the serum concentration-time data (Cmax) of efimosfermin alfa

    Time frame: Up to 90 days

Secondary outcomes

  1. Time to maximum observed serum drug concentration (Tmax) of efimosfermin alfa

    Time frame: Up to 90 days

  2. Apparent terminal phase half-life (t1/2) of efimosfermin alfa

    Time frame: Up to 90 days

  3. Area under the serum drug concentration versus time curve from time zero to 45 days [AUC(0-45days)] of efimosfermin alfa

    Time frame: Up to 45 days

  4. Area under the serum drug concentration versus time curve from time zero to 60 days [AUC(0-60days)] of efimosfermin alfa

    Time frame: Up to 60 days

  5. Area under the serum drug concentration versus time curve from time zero to 90 days [AUC(0-90days)] of efimosfermin alfa

    Time frame: Up to 90 days

  6. Time of last quantifiable plasma drug concentration (Tlast) of efimosfermin alfa

    Time frame: Up to 90 days

  7. Apparent clearance (CL/F) of efimosfermin alfa

    Time frame: Up to 90 days

  8. Apparent volume of distribution (Vz/F) of efimosfermin alfa

    Time frame: Up to 90 days

07

Study locations

1 site
  • GSK Investigational Site
    Auckland, 1010, New Zealand
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2026 to primary completion in Aug 2026, 5 months.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Jan 13, 2026
StartActual
Mar 5, 2026
Primary completionActual
Aug 13, 2026
CompletionActual
Aug 13, 2026
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07335198
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 13, 2026
Start date
Mar 5, 2026
Primary completion
Aug 13, 2026
Completion
Aug 13, 2026
Last update
Sep 21, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efimosfermin alfa

Start the discussion